Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II basket study of necitumumab in EGFR amplification-positive metastatic solid tumors
jRCTs041220070Phase 2Completed
- Sponsor
- Aichi Cancer Center
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of necitumumab in esophageal cancer, gastric cancer (GC), small bowel cancer and 2 more, sponsored by Aichi Cancer Center. Primary endpoint: Objective response rate. Started Oct 2022; status: completed.
02
Drugs
necitumumab
03
Conditions
esophageal cancergastric cancer (GC)small bowel cancertransitional cell carcinoma (TCC)breast cancer
Beyond the preview
Go deeper on jRCTs041220070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041220070.